Get the Stockscreener App
84.46
1.60%
1.33
After Hours:
84.50
0.04
+0.05%
Oruka Therapeutics Inc stock is traded at $84.46, with a volume of 2.01M.
It is up +1.60% in the last 24 hours and up +40.44% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$83.13
Open:
$83.14
24h Volume:
2.01M
Relative Volume:
1.11
Market Cap:
$5.09B
Revenue:
-
Net Income/Loss:
$-116.25M
P/E Ratio:
-35.32
EPS:
-2.3912
Net Cash Flow:
$-91.19M
1W Performance:
-11.25%
1M Performance:
+40.44%
6M Performance:
+203.70%
1Y Performance:
+535.52%
1-Day Range:
$82.53
$89.85
1-Week Range:
$82.22
$96.14
52-Week Range:
$12.84
$97.78
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
84.46 | 5.01B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics (ORKA) Sees 8.1% Decline - GuruFocus
Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing - marketscreener.com
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares - Benzinga
Form 13D/A ORUKA THERAPEUTICS For: 1 July By Investing.com - Investing.com India
Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock By Investing.com - Investing.com Australia
Form 144 | Oruka Therapeutics(ORKA.US) Insider Proposes to Sell 300.01 Million in Common Stocks - Moomoo
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Form 144 Oruka Therapeutics For: 1 July By Investing.com - Investing.com Nigeria
Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock - Investing.com
Form 144 Oruka Therapeutics For: 1 July - Investing.com UK
Why Oruka Therapeutics (ORKA) Is Up 13.6% After Russell Index Reclassification Into Growth Benchmarks - simplywall.st
Oruka Therapeutics COO Laura Sandler sells $472,078 in stock - Investing.com
Oruka Therapeutics COO Laura Sandler sells $472,078 in stock By Investing.com - Investing.com South Africa
Form 4 Oruka Therapeutics Inc For: 1 July By Investing.com - Investing.com India
Form 4 Oruka Therapeutics Inc For: 1 July - Investing.com UK
Price to book forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News - Insider Monkey
Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says - marketscreener.com
UBS raises Oruka Therapeutics stock price target to $130 on efficacy data outlook - Investing.com Australia
Price to book forward of Oruka Therapeutics, Inc. – XETR:HQ1 - TradingView
Top 10 Hot Stocks with the Highest Upside Potential - Insider Monkey
Oruka Therapeutics stock hits 52-week high at 91.2 USD By Investing.com - Investing.com Australia
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell 3000E Index - marketscreener.com
Oruka Therapeutics stock hits 52-week high at 91.2 USD - Investing.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 2000 Growth Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM:ORKA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000E Growth Benchmark - marketscreener.com
Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150 - Moomoo
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell Microcap Index - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) dropped from Russell 2500 Value Benchmark - marketscreener.com
Oruka Therapeutics, Inc.(NasdaqGM:ORKA) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
Enterprise value to EBITDA forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Oruka Therapeutics, Inc.(NasdaqGM: ORKA) added to Russell 3000 Growth Benchmark - marketscreener.com
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean - Yahoo Finance
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean - The Motley Fool
Oruka Therapeutics, Inc. Actuals & Estimates (DUS:HQ1) - TradingView
Enterprise value to revenue forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
Price to earnings forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
ORKA Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of Oruka Therapeutics, Inc. – NASDAQ:ORKA - TradingView
HQ1 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? - AOL.com
Price to book forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Price to sales forward of Oruka Therapeutics, Inc. – TRADEGATE:HQ1 - TradingView
Oruka Therapeutics, Inc. (NASDAQ: ORKA) Share Price, ORKA Stock News, ORKA Share Price & Updates - Kalkine
Oruka Therapeutics (ORKA) Is Up 5.1% After Positive Trial Update And Insider Share SalesWhat's Changed - Sahm
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Jul 01 '26 |
Sale |
84.43 |
3,553,410 |
300,014,406 |
1,131,954 |
| Sandler Laura Lee | Chief Operating Officer |
Jul 01 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
241,384 |
| Sandler Laura Lee | Chief Operating Officer |
Jul 01 '26 |
Sale |
94.42 |
5,000 |
472,079 |
236,384 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 22 '26 |
Sale |
80.95 |
1,587 |
128,468 |
15,312 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 12 '26 |
Option Exercise |
15.88 |
9,459 |
150,175 |
26,753 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 12 '26 |
Sale |
69.72 |
9,459 |
659,508 |
17,294 |
| Agarwal Arjun | Senior Vice President, Finance |
Jun 15 '26 |
Sale |
69.69 |
395 |
27,528 |
16,899 |
| Goncalves Joana | Chief Medical Officer |
Jun 15 '26 |
Option Exercise |
7.32 |
7,000 |
51,240 |
40,665 |
| Goncalves Joana | Chief Medical Officer |
Jun 15 '26 |
Sale |
69.28 |
7,947 |
550,607 |
32,718 |
| Klein Lawrence Otto | Chief Executive Officer |
Jun 15 '26 |
Sale |
69.69 |
1,729 |
120,494 |
925,580 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):